Abstracts tagged "Ankylosing spondylitis (AS)"

Abstract Number: 1756 • ACR Convergence 2025
Exosomal Cargo and Surface Markers: Informative Signals in Axial Spondyloarthritis
Fataneh Tavasolian¹, star lively², chiara Pastrello³, Melissa Lim¹, Addison Pacheco⁴, Zoya Qaiyum⁵, Michael Tang⁴, Zeynep Baskurt³, Igor Jurisica⁶, Mohit Kapoor⁵ and Robert Inman⁴, ¹University of Toronto, Toronto, ON, Canada, ²University Heaklth Network, Toronto, ³University Health Network, Toronto, ⁴University Health Network, Toronto, ON, Canada, ⁵Schroeder Arthritis Institute, University Health Network, Toronto, ON, Canada, ⁶University Health Network, Toronto, Canada
Background/Purpose: Exosomes are small extracellular vesicles carrying surface molecules and molecular cargo, including microRNAs (miRNAs), that mediate intercellular communication. Both the exosomal cargo and surface…
Abstract Number: 1438 • ACR Convergence 2025
Similar Efficacy of Bimekizumab in Two Clinical Endotypes of Axial Spondyloarthritis: 2-Year Results from Two Phase 3 Studies and Their Open-Label Extension
Félicie Costantino¹, Ann-Sophie De Craemer², Filip Van den Bosch², Maxime Breban³, Vanessa Taieb⁴, Diana Voiniciuc⁵, Natasha de Peyrecave⁶, Dirk Elewaut⁷ and Maria-Antonietta D'Agostino⁸, ¹Department of Rheumatology, Ambroise Paré Hospital, AP-HP, Paris, France and Infection & Inflammation, UMR ¹¹⁷³, Inserm, UVSQ/Université Paris Saclay, Montigny-Le-Bretonneux, France, ²Department of Internal Medicine and Pediatrics, Ghent University and VIB Center for Inflammation Research, Ghent, Belgium, ³CHU Ambroise-Paré, Boulogne-Billancourt, France, ⁴UCB, Colombes, France, ⁵UCB, Slough, United Kingdom, ⁶UCB, Brussels, Belgium, ⁷VIB Center for Inflammation Research, and Ghent University Hospital, Department of Rheumatology, Ghent, Belgium, ⁸Department of Rheumatology, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del Sacro Cuore, Rome, Italy
Background/Purpose: Axial spondyloarthritis (axSpA) is a chronic inflammatory disease mainly affecting the sacroiliac joints and spine.1 Peripheral manifestations are common, contributing to disease burden.2 Two…
Abstract Number: 0559 • ACR Convergence 2025
Impact of Secukinumab on Cardiovascular Disease in Patients with Psoriasis, PsA, and Axial Spondyloarthritis: A Systematic Review of Existing Evidence
Javier R Godo¹, Christopher EM Griffiths², Miguel A. González-Gay³, Andreas Clemens⁴, Cynthia Vizcaya⁴, Lara Gómez⁵ and Nehal N Mehta⁶, ¹Department of Rheumatology and Joint and Bone Research Unit, Hospital Universitario Fundación Jiménez Díaz, and Instituto de Investigación Sanitaria-Fundación Jiménez Díaz, Madrid, Spain, ²Centre for Dermatology Research, Manchester Academic Health Science Centre, The University of Manchester, Manchester, UK and Department of Dermatology, King's College Hospital NHS Foundation Trust, King's College London, London, United Kingdom, ³Department of Rheumatology and Joint and Bone Research Unit, Hospital Universitario Fundación Jiménez Díaz, and Instituto de Investigación Sanitaria-Fundación Jiménez Díaz, Madrid, Spain, and Medicine and Psychiatry Department, University of Cantabria, Santander, Spain, ⁴Novartis Pharma AG, Basel, Switzerland, ⁵Novartis Farmaceutica, Madrid, Spain, ⁶The George Washington University School of Medicine and Health Sciences, Washington DC
Background/Purpose: Psoriasis, psoriatic arthritis (PsA), and axial spondyloarthritis (axSpA) are associated with increased risk of cardiovascular (CV) disease driven by chronic systemic inflammation, with IL-17A…
Abstract Number: 0102 • ACR Convergence 2025
Iron Metabolism Dysregulation and Inflammation in Ankylosing Spondylitis: Role of SLC39A14 in Extracellular Matrix Remodeling
Dachun Zhuo¹, Yulong Tang², Xiaobei Ma², Chengchun Geng¹, Jiangnan Xie¹, Jiucun Wang² and Jing Liu¹, ¹Fudan University, Shanghai, Shanghai, China (People's Republic), ²Fudan university, Shanghai, China (People's Republic)
Background/Purpose: Iron metabolism dysregulation has been increasingly recognized as a key factor in the pathogenesis of inflammatory arthritis, with evidence linking altered iron homeostasis to…
Abstract Number: 2353 • ACR Convergence 2025
Efficacy of Vunakizumab in Reducing Pain in Ankylosing Spondylitis: A Post-Hoc Analysis of a Phase 2/3 Clinical Trial
Jian Xu, Yifan Yang, Shuang Liu, Ru Bai, Shu Li, Guofang Zhang, Xiangyu Wang, Xinyu Xu, Mai Zheng and Daying Feng, The First Affiliated Hospital of Kunming Medical University, Kunming, China (People's Republic)
Background/Purpose: Ankylosing spondylitis (AS) is a chronic inflammatory disease that primarily affects the spine and sacroiliac joints, resulting in significant pain, stiffness, and functional impairment.…
Abstract Number: 1754 • ACR Convergence 2025
B3GNT2 Regulates Integrin β3 Glycosylation and Th17/Treg Imbalance in Axial Spondyloarthritis Pathogenesis
Chengchun Geng¹, Dachun Zhuo¹, Jiucun Wang² and Jing Liu¹, ¹Fudan University, Shanghai, Shanghai, China (People's Republic), ²Fudan University, Shanghai, China (People's Republic)
Background/Purpose: The rs6759298 variant near B3GNT2 is associated with Axial Spondyloarthritis (AS); however, its pathogenic mechanisms remain unknown. In this study, we explored the role…
Abstract Number: 1433 • ACR Convergence 2025
Identifying Predictors of Difficult-to-Manage Axial Spondyloarthritis: Real-World Insights from a Taiwanese Registry Cohort
Yen-An Chang and Ming-Han Chen, Division of Allergy, Immunology & Rheumatology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan, Taipei, Taiwan (Republic of China)
Background/Purpose: The concept of Difficult-to-Manage Axial Spondyloarthritis (D2M-ax-SpA) was recently introduced by the Assessment of Spondyloarthritis International Society (ASAS). According to this new definition, D2M-ax-SpA…
Abstract Number: 0554 • ACR Convergence 2025
Real world experience with generic Tofacitinib in Axial Spondyloarthritis from North India
Sanjeev Kapoor¹, Babita Bondage¹, Niti Kedia¹, Mariya Patel¹ and Akanksha Kapoor², ¹Indian Spinal Injuries Centre (ISIC), New Delhi, India, ²Bharati Vidyapeeth (Deemed to be University) Medical College and Hospital, Pune, India
Background/Purpose: Axial spondyloarthritis (AxSpA) is an inflammatory condition that falls under the category of spondyloarthritis (SpA) and significantly affects quality of life, causing symptoms like…
Abstract Number: 0098 • ACR Convergence 2025
The Deubiquitinase TRABID is a Regulator of Osteogenesis and Inflammation in Spondyloarthritis:
Archita Srinath¹, Sungsin Jo², Daniele Mauro³, Mariia Korshko⁴, Mansi Aparnathi⁵, Shaghayegh Foroozan Boroojeni⁶, Tae-Hwan Kim⁷, Francesco Ciccia⁸ and Nigil Haroon⁹, ¹University of Toronto, Toronto, ON, Canada, ²Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea, ³University of Campania, Italy, Naples, Italy, ⁴UHN, Toronto, ON, Canada, ⁵Schroeder Arthritis Institute, University Health Network, Toronto, ON, Canada, ⁶University Health Network/University of Toronto, Toronto, ON, Canada, ⁷Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea, ⁸University of Campania, Naples, Italy, ⁹Department of Medicine/Rheumatology, University Health Network, Schroeder Arthritis Institute, University of Toronto, Toronto, ON, Canada
Background/Purpose: Axial Spondyloarthritis (AxSpA) is characterized by both inflammation and new bone formation. Current therapeutic targets aim to control inflammation, however over 40% of patients…
Abstract Number: 2346 • ACR Convergence 2025
Back in Action: Six Months of Biological Therapy Improve Sexual Function in Men with Ankylosing Spondylitis
Daniel Zavada¹, Barbora Vala², Adela Navratilova², Veronika Losterova², Lenka Moravcova², Jiri Vencovsky³, Ladislav Šenolt⁴, Karel Pavelka⁵ and Michal Tomcik⁵, ¹Institute of Rheumatology, Prague; Charles University, Third Faculty of Medicine, Hlavné mesto Praha, Czech Republic, ²Institute of Rheumatology, Praha, Czech Republic, ³Institute of Rheumatology, Praha ⁸, Czech Republic, ⁴Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, ⁵Institute of Rheumatology and Department of Rheumatology, ¹st Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic
Background/Purpose: Ankylosing spondylitis (AS) significantly impacts quality of life across multiple domains. To date, no studies have evaluated the impact of initial biological therapy on…
Abstract Number: 1752 • ACR Convergence 2025
Prg4+ Ligament Cells Are Involved in Ligament Ossification in Ankylosing Spondylitis
Kunhai Tang¹, Lilu Zu¹, Chenyuan Wu¹, Jiucun Wang¹ and Jing Liu², ¹Fudan University, shanghai, China (People's Republic), ²Fudan University, Shanghai, Shanghai, China (People's Republic)
Background/Purpose: Ankylosing spondylitis(AS) is a chronic inflammatory disease with clinical symptoms characterized by inflammatory low back pain and spinal ankylosis due to ligament ossification. Enthesitis…
Abstract Number: 1429 • ACR Convergence 2025
Survival Outcomes in Elderly Patients with Axial Spondyloarthritis and Concomitant Cancer
Savannah Bowman¹, Mei Li², Xiudong Lei³, Hui Zhao³, Juan Ruiz⁴, Sharon H. Giordano³, Alexis Ogdie⁵ and Maria Suarez-Almazor⁶, ¹Baylor College of Medicine, Houston, ²The University of Texas Health Science Center at Houston, Houston, ³The University of Texas MD Anderson Cancer Center, Houston, ⁴Hospital Alemán, Buenos Aires, Argentina, ⁵University of Pennsylvania, Philadelphia, PA, ⁶MD Anderson Cancer Center, Houston, TX
Background/Purpose: Axial spondyloarthritis (axSpA) is associated with several comorbidities, including cancer. Prior studies have shown that elderly patients with rheumatoid arthritis and concomitant breast or…
Abstract Number: 0553 • ACR Convergence 2025
Modified A-Tool: An online self-screening tool for axial spondyloarthritis for patients with chronic back pain
Zeyu Tang¹ and Abhijeet Danve², ¹Yale School of Medicine, New Haven, CT, ²Section of Rheumatology, Department of Medicine, Yale School of Medicine, New Haven, CT
Background/Purpose: Lack of timely rheumatology referral of chronic back pain (CBP) patients with suspected axial spondyloarthritis (axSpA) is a major contributor to delayed diagnosis. We…
Abstract Number: 2347 • ACR Convergence 2025
Bimekizumab Treatment Resulted in Patients with Axial Spondyloarthritis Maintaining Their Clinical Responses Over 3 Years: Results from Two Phase 3 Studies and Their Open-Label Extension
Fabian Proft¹, Désirée Van Der Heijde², Sergio Schwartzman³, Vanessa Taieb⁴, Sarah Kavanagh⁵, Gaëlle Varkas⁶, Victoria Navarro-Compan⁷ and Xenofon Baraliakos⁸, ¹Department of Gastroenterology, Infectiology and Rheumatology (including Nutrition Medicine), Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, ²Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ³Weill Cornell Medical Center, New York Presbyterian Hospital, and Hospital for Special Surgery, New York, NY, ⁴UCB, Colombes, France, ⁵UCB, Morrisville, NC, ⁶Department of Rheumatology, Ghent University Hospital, Ghent, Belgium, ⁷Department of Rheumatology, La Paz University Hospital, IdiPaz, Madrid, Spain, ⁸Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany
Background/Purpose: Axial spondyloarthritis (axSpA) is a chronic inflammatory disease which requires optimal management.1 In clinical trials, Assessment of SpondyloArthritis international Society ≥40% improvement (ASAS40) is…
Abstract Number: 1715 • ACR Convergence 2025
Spondyloarthritis and Psoriatic Arthritis Patients Under Immunosuppressive Conventional and Biologic DMARDs: Favorable Disease Safety and Attenuated Immunogenicity Following Recombinant Herpes Zoster Vaccination
Carla Saad¹, Eduardo Borba², Fernanda Chaer³, Ana C Medeiros-Ribeiro¹, Sandra G Pasoto¹, Nadia Emi Aikawa⁴, Luisa Correia⁵, Percival Sampaio-Barros⁶, Julio Moraes⁷, Murillo Dorio¹, Claudia Goldenstein-Schainberg¹, Clovis Artur Silva⁸ and Eloisa Bonfa², ¹Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, Sao Paulo, Brazil, ²Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, São Paulo, Brazil, ³Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, Santos, Brazil, ⁴Rheumatology Division and Pediatric Rheumatology Unit, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, Sao Paulo, São Paulo, Brazil, ⁵Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, Sao Paulo, ⁶Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, São Paulo, Brazil, ⁷Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, Jundiai, Brazil, ⁸University of São Paulo, São Paulo, São Paulo, Brazil
Background/Purpose: Psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA) patients are at increased risk for herpes zoster(HZ) due to impaired cell-mediated immunity associated with the underlying…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].